Burden of hepatitis B-associated diseases in China from 1990 to 2030.
10.16250/j.32.1374.2023068
- Author:
L YAO
1
;
S LIN
1
;
J HUANG
1
;
Y WU
1
Author Information
1. Department of Hepatology, the First Affiliated Hospital of Fujian Medical University; Hepatology Research Institute, Fujian Medical University; Fujian Clinical Research Center for Hepatopathy and Intestinal Diseases, Fuzhou, Fujian 350005, China.
- Publication Type:Journal Article
- Keywords:
Burden of disease;
China;
Disability-adjusted life year;
Hepatitis B;
Incidence;
Joinpoint regression analysis;
Mortality;
Prevalence
- MeSH:
Male;
Female;
Humans;
Middle Aged;
Aged;
Bayes Theorem;
Quality-Adjusted Life Years;
Hepatitis B/epidemiology*;
Liver Neoplasms/epidemiology*;
China/epidemiology*;
Incidence
- From:
Chinese Journal of Schistosomiasis Control
2023;35(5):464-475
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To measure the burden of hepatitis B-associated diseases in China from 1990 to 2019, and to predict its changes from 2020 to 2030.
METHODS:The age-standardized prevalence, incidence, mortality and disability-adjusted life years (DALY) rate of hepatitis B-associated diseases in China from 1990 to 2019 were extracted from the Global Burden of Disease 2019 (GBD 2019) data resources, and the trends in burdens of hepatitis B-associated diseases were evaluated from 1990 to 2019 using estimated annual percentage change (EAPC) and annual percent change (APC). In addition, the changes in the burden of hepatitis B-associated diseases were predicted in China from 2020 to 2023 using the Bayesian model.
RESULTS:The overall incidence of hepatitis B-associated diseases reduced from 2 725.98/105 in 1990 to 1 397.31/105 in 2019 in China [estimated annual percentage change (EAPC) = -2.35%, 95% confidential interval (CI): (-2.58%, -2.13%)], with a reduction in the prevalence from 12 239.53/105 in 1990 to 6 566.12/105 in 2019 [EAPC = -2.34%, 95% CI: (-2.54%, -2.14%)], a reduction in the mortality from 24.67/105 in 1990 to 8.07/105 in 2019 [EAPC = -4.92%, 95% CI: (-5.37%, -4.47%)], and a reduction in the DALY rate from 793.38/105 in 1990 to 247.71/105 in 2019 [(EAPC = -5.15%, 95% CI: (-5.64%, -4.66%)]. The DALY rate of hepatitis B-associated diseases were mainly attributed to liver cancer, and the DALY rate of hepatitis B-associated diseases appeared a tendency towards a rise in China from 2012 to 2019 [APC = 1.30%, 95% CI: (0.16%, 2.45%)]. The overall burden of hepatitis Bassociated diseases was higher in males than in females, and the DALY rate of hepatitis B-associated diseases increased with age, with the greatest DALY rate seen among patients at ages of 50 to 69 years. The overall incidence of hepatitis B-associated diseases was projected to be 866.79/105 in China in 2030, with the greatest incidence seen in acute hepatitis B (854.87/105), and the burden of hepatitis B-associated diseases was predicted to decline in China from 2020 to 2030; however, the burden of liver disease was projected to appear a tendency towards a rise.
CONCLUSIONS:The burden of hepatitis B-associated diseases appears an overall tendency towards a decline in China from 1990 to 2030; however, the burden of liver cancer appears a tendency towards aggravation. Early diagnosis and treatment of liver cancer should be given a high priority.
